Search | IOVS | ARVO Journals

Showing 1 – 20 of 26

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract July 2018

Efficacy of EYS606 in Experimental Models of Uveitis

Ronald BUGGAGE; Karine Bigot; Elodie Touchard; Romain Benard; Thierry Bordet; Francine F Behar-Cohen

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1191. doi:

ARVO Annual Meeting Abstract July 2018

A Non-Viral Gene Therapy Approach for Retinitis Pigmentosa

Karine Bigot; Pauline Gondouin; Pierrick Montagne; Romain Benard; Emilie Picard; Yves G Courtois; Ronald Buggage; Thierry Bordet; Francine F Behar-Cohen

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):5655. doi:

ARVO Annual Meeting Abstract July 2018

Non-Clinical Safety of Ciliary Muscle Electrotransfection

Thierry Bordet; Karine Bigot; Romain Benard; Jean-Denis Laffitte; Elodie Touchard; Ronald Buggage; Francine F Behar-Cohen

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):5679. doi:

ARVO Annual Meeting Abstract June 2017

One Year Results of a Phase I/IIa Study of SAR422459 in Patients with Stargardt Macular Degeneration (SMD)

David J Wilson; Jose Alain Sahel; Richard G Weleber; Laura R Erker; Andreas K Lauer; Tim Stout; Isabelle S Audo; Saddek Mohand-Said; Pierre-Olivier Barale; Laurence Titeux; Ronald BUGGAGE

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):3385. doi:

ARVO Annual Meeting Abstract June 2017

Natural History of Stargardt Disease: Patients’ profile at clinical diagnosis

Catherine Brun-Strang; Andrea PISCOPO; Ronald BUGGAGE; Joseph MILCE; Rahma SELLAMI

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1487. doi:

ARVO Annual Meeting Abstract June 2017

Living with Usher’s syndrome Type 1: Development of a disease impact model from qualitative interviews with patients and their parents

Andrea PISCOPO; Aude ROBOREL de CLIMENS; Catherine Brun-Strang; Ronald BUGGAGE; Carla Dias Barbosa; Naomi KNOBLE

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1355. doi:

ARVO Annual Meeting Abstract June 2017

Understanding the impact of Stargardt disease on patients’ lives: Insights from patients and their parents based on qualitative research

Aude ROBOREL de CLIMENS; Andrea PISCOPO; Catherine Brun-Strang; Ronald BUGGAGE; Carla Dias Barbosa; Béatrice Tugaut

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1356. doi:

ARVO Annual Meeting Abstract June 2017

Safety Profile of the Surgical Procedure for the Administration of Ocular Gene Therapies

Ronald BUGGAGE; Pierre-Olivier Barale; Sarah Ayello-Scheer; Andreas K Lauer; Tim Stout; Isabelle S Audo; Saddek Mohand-Said; Jose Alain Sahel; Paul Yang; Mark E Pennesi; Richard G Weleber; Laurence Titeux; Amel Lahmar; Preethi A Sundaram

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1491. doi:

ARVO Annual Meeting Abstract June 2017

3-Year Interim Safety Profile of Adeno-Associated Virus Serotype 2-soluble Variant of the Vascular Endothelial Growth Factor Receptor Type 1 (AAV2-sFLT01) Administered by Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration

Rafael Varona; Annaig Le-Halpere; Peter A Campochiaro; Jeffrey Heier; Pravin U Dugel; Mark Barsamian; Annie Purvis; Mario Cabrera-Salazar; Cheryl Delacono; Najwa Mostafa; Abraham Scaria; Ronald BUGGAGE

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2321. doi:

ARVO Annual Meeting Abstract June 2017

Natural History of Retinal function and structure in a French cohort of patients with Usher Syndrome Type 1 due to MYO7A Mutations.

Saddek Mohand-Said; Line Azoulay-Sebban; Isabelle S Audo; Céline Chaumette; Céline Devisme; Karine Becker; Emmanuel Gutman; Caroline Segaut-Prevost; Ronald BUGGAGE; Jose Alain Sahel

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4679. doi:

ARVO Annual Meeting Abstract September 2016

Variability in vitreous haze grading technique using a 9-step logarithmic scale in patients enrolled in the Sarilumab in Non-infectious Uveitis (SARIL-NIU), the Saturn Study

Marc D de Smet; Preethi A Sundaram; Kristine Erickson; Valerie Corp-dit-Genti; Laetitia Vinet; Robert Vitti; Ronald BUGGAGE; Quan Dong Nguyen

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12) doi:

ARVO Annual Meeting Abstract September 2016

Natural History of Early-Onset Stargardt Disease

Ronald BUGGAGE; Andrea Piscopo; Joseph Milce; Perrine Le Calve; Catherine Brun-Strang

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2065. doi:

ARVO Annual Meeting Abstract June 2015

Early findings in a Phase I/IIa clinical program for Stargardt disease (STGD1, MIM #248200)

Isabelle S Audo; Richard G Weleber; Tim Stout; Andreas K Lauer; Mark E Pennesi; Saddek Mohand-Said; Pierre-Olivier Barale; Ronald Buggage; David J Wilson; Jose Alain Sahel

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):3819. doi:

ARVO Annual Meeting Abstract June 2015

Foveal detachment in patients undergoing gene therapy for Stargardt disease (STGD1, MIM #248200)

Maria Parker; Richard G Weleber; Tim Stout; Laura Erker; Isabelle S Audo; Saddek Mohand-Said; Pierre-Olivier Barale; Ronald Buggage; Jose Alain Sahel; David J Wilson

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):520. doi:

ARVO Annual Meeting Abstract June 2015

The clinical course of Stargardt disease in a French cohort of patients.

Saddek Mohand-Said; Catherine Brun-Strang; Ronald BUGGAGE; Konstantinos Aliferis; Isabelle S Audo; Caroline Amand; Ieva Sliesoraityte; Alain Stemart; Jose Alain Sahel

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2861. doi:

ARVO Annual Meeting Abstract June 2015

Stargardt Disease - A patient’s journey across the world

Ronald BUGGAGE; Majorie Leclerc; Genevieve Bonnelye; Catherine Brun-Strang

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2141. doi:

ARVO Annual Meeting Abstract June 2015

Stargardt Disease: burden from a patient association perspective.

Catherine Brun-Strang; Genevieve Bonnelye; Majorie Leclerc; Ronald BUGGAGE

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2142. doi:

ARVO Annual Meeting Abstract June 2015

Early findings in a Phase I/IIa clinical program for Usher syndrome 1B (USH1B; MIM #276900)

Richard G Weleber; Tim Stout; Andreas K Lauer; Mark E Pennesi; Isabelle S Audo; Saddek Mohand-Said; Pierre-Olivier Barale; Ronald Buggage; Jose Alain Sahel; David J Wilson

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):2286. doi:

ARVO Annual Meeting Abstract June 2013

Phase I, Randomized, Double-Masked, Vehicle-Controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of Recombinant Human Nerve Growth Factor Eye Drops in Healthy Volunteers

Ronald Buggage; Pier Ruffini; Mauro Ferrari

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):1944. doi:

ARVO Annual Meeting Abstract March 2012

The Influence of Seasonality and Subtype in Vernal Keratoconjunctivitis (VKC) Patients in a Randomized Clinical Trial Investigating NOVA22007, a preservative-free cyclosporine cationic emulsion

Mourad Amrane; Andrea Leonardi; Dominique Bremond-Gignac; Maeva Deniaud; Dahlia Ismail; Christophe Baudouin; Ronald Buggage

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):4011. doi:

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Efficacy of EYS606 in Experimental Models of Uveitis

A Non-Viral Gene Therapy Approach for Retinitis Pigmentosa

Non-Clinical Safety of Ciliary Muscle Electrotransfection

One Year Results of a Phase I/IIa Study of SAR422459 in Patients with Stargardt Macular Degeneration (SMD)

Natural History of Stargardt Disease: Patients’ profile at clinical diagnosis

Living with Usher’s syndrome Type 1: Development of a disease impact model from qualitative interviews with patients and their parents

Understanding the impact of Stargardt disease on patients’ lives: Insights from patients and their parents based on qualitative research

Safety Profile of the Surgical Procedure for the Administration of Ocular Gene Therapies

3-Year Interim Safety Profile of Adeno-Associated Virus Serotype 2-soluble Variant of the Vascular Endothelial Growth Factor Receptor Type 1 (AAV2-sFLT01) Administered by Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration

Natural History of Retinal function and structure in a French cohort of patients with Usher Syndrome Type 1 due to MYO7A Mutations.

Variability in vitreous haze grading technique using a 9-step logarithmic scale in patients enrolled in the Sarilumab in Non-infectious Uveitis (SARIL-NIU), the Saturn Study

Natural History of Early-Onset Stargardt Disease

Early findings in a Phase I/IIa clinical program for Stargardt disease (STGD1, MIM #248200)

Foveal detachment in patients undergoing gene therapy for Stargardt disease (STGD1, MIM #248200)

The clinical course of Stargardt disease in a French cohort of patients.

Stargardt Disease - A patient’s journey across the world

Stargardt Disease: burden from a patient association perspective.

Early findings in a Phase I/IIa clinical program for Usher syndrome 1B (USH1B; MIM #276900)

Phase I, Randomized, Double-Masked, Vehicle-Controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of Recombinant Human Nerve Growth Factor Eye Drops in Healthy Volunteers

The Influence of Seasonality and Subtype in Vernal Keratoconjunctivitis (VKC) Patients in a Randomized Clinical Trial Investigating NOVA22007, a preservative-free cyclosporine cationic emulsion

To View More...

You must be signed into an individual account to use this feature.